About this trial
This is a multicentre, phase 2 study in patients with non-small cell lung cancer. This study is looking at adding relatlimab (anti LAG-3 checkpoint inhibitor) to nivolumab plus chemotherapy and comparing it to nivolumab plus chemotherapy. The objective of the trial is to confirm the dose safety of these drugs when combined and to compare the progression free survival.
Patient Profile
Participants with previously untreated Stage IV Non-Small Cell Lung Cancer.
Where’s this trial being run?
Beaumont Hospital and St Vincents University Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | CA224-104 (RELATIVITY) |
|---|---|
| Number: | 21-12 |
| Full Title: | A Phase 2 Randomized Double-blind Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) |
| Principal Investigator: | Dr Jarushka Naidoo |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | Bristol-Myers Squibb |
| Recruitment Started: |
Global: 15-Feb-2021 Ireland: 30-Jul-2021 |
| Global Recruitment Target: | 520 |
|---|---|
| Ireland Recruitment Target: | 6 |